QLS-101 is under clinical development by Qlaris Bio and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase II drugs for Ocular Hypertension have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QLS-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QLS-101 overview

QLS-101 is under development for the treatment of ocular hypertension, normal tension glaucoma, Sturge-weber syndrome and open-angle glaucoma. The drug candidate is a ATP-sensitive potassium (KATP) channel modulator. It is administered through ophthalmic route in the form of drops.

Qlaris Bio overview

Qlaris Bio discovers and develops novel therapeutics targeting ophthalmic diseases. The company’s lead program QLS-101, a novel topical ocular therapy, that lowers intraocular pressure with ATP sensitive potassium (KATP) channel modulator, by lowering episcleral venous pressure (EVP) and improves outflow distal to the trabecular meshwork. It is also investigating EVP-targeted therapies targeting sturge-weber syndrome and normal tension glaucoma. The company is a spinout of Qrativ a biotechnology incubator between Mayo Clinic and Nference. Qlaris Bio is headquartered in Wellesley, Massachusetts, the US.

For a complete picture of QLS-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.